12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Botox onabotulinumtoxinA regulatory update

Allergan disclosed in its 1Q12 earnings that it submitted a regulatory application to Health Canada for Botox onabotulinumtoxinA to treat overactive bladder (OAB) with symptoms of urinary incontinence, urgency and frequency in adults with an inadequate response to or intolerant of anticholinergic treatment. Earlier this year, Allergan said it submitted an sBLA...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >